In addition, the use of LDLR inhibitors may also have potential therapeutic value as a means of increasing cellular CoQ10 levels in other patient groups which have been associated with a deficiency in the level of this isoprenoid, such as those with cardiovascular disease [75]. This evidence concerns the gene LDLR and cardiovascular disorder.